10 Best Stocks to Buy for the Next 10 Years

10 Best Stocks to Buy for the Next 10 Years

In this piece, we will take a look at the ten best stocks to buy for the next ten years. For more stocks, head on over to 5 Best Stocks to Buy for the Next 10 Years.

The time value of money is a basic financial concept that is taught in business schools worldwide. Simply put, a dollar today is worth more today than it will be worth tomorrow. While this sound counterintuitive to many, the simple (and perhaps most popular) concept of inflation is behind this insidious development. Price rises are a universal truth, and since they go up in the future, today’s money can buy more goods than the same money tomorrow.

This basic principle is behind the entire finance industry. Every day countless banks, hedge funds, and investment managers scour through strategies to ensure that their investors’ money retains, and even grows, its value over time. The most basic method to do this is to simply open a bank savings account. Banks are legally required to pay their depositors an interest rate that is a certain amount of points below the Federal Reserve’s benchmark rate. In fact, savings accounts, and bonds, are also the main reason the central bank raises interest rates to combat inflation. The logic behind increasing rates goes as follows: higher rates remove cash from circulation by accumulating it into banks and financial instruments and therefore result in demand reduction for products and services. This in turn produces lower strain on their manufacturers to increase production, which then ends up reducing their manufacturing costs and therefore drives down prices.

Yet, while bank deposits offer a stable return, this return is often not enough to outpace inflation. Therefore, those with a higher risk appetite turn to aggressive means to grow their earnings, and one of the most popular ones is the stock market. The simple fact that drives investors in droves to the market is returns. For instance, if you could go back in time and just invest $1 to buy a single share of Warren Buffett’s Berkshire Hathaway Inc. (NYSE:BRK-A), you’d have a whopping $52,826 today! Unbelievable, right? Of course, this is just a hypothetical situation since back in 1983, this wouldn’t have been possible since buying fractional shares was not allowed back then. In 1983, a Berkshire Hathaway Inc. (NYSE:BRK-A) share traded for $870 ($2,613 in today’s money), so you’d have to spend this much and see your investment bloom to $460,462 today.

This is the magic of long term investing. However, as easy as it sounds on paper, holding on to shares for decades requires fortitude, and no one other than Ken Fisher of Fisher Investments puts it better:

In my Only Three Questions book many years ago, I wrote about a fact that was true then and is true now. Most people are wrong more than they are right in investment. The greatest investors of all time, those legendary ones, are only right about 70{1668a97e7bfe6d80c144078b89af180f360665b4ea188e6054b2f93f7302966b} of the time. What makes them so good, is that when they’re wrong, they actually don’t have that make them do stupid stuff. It doesn’t impact them into doing something crazy If you are right 70{1668a97e7bfe6d80c144078b89af180f360665b4ea188e6054b2f93f7302966b} of the time, you’re wrong 30{1668a97e7bfe6d80c144078b89af180f360665b4ea188e6054b2f93f7302966b} of the time, and to become that, you gotta be perfectly comfortable being wrong a lot. And that wrong tends to come in clumpy periods. So you’re wrong, and wrong again, and wrong again, and wrong again before you’re right. And you gotta not, you cannot be so upset being a whole lot wrong that it drives you off into doing something.

Most people don’t have that fortitude. Most people end up doing something when the thing has being going against them for a little while. And that’s why passive which is a perfectly fine thing to do, passive tools are perfectly fine, is very hard for people to do. You yourself have to set it, and forget it for decades. Most people can’t do that. Few people can. You, if you want to think about being a passive investor, which I think is a fine thing to think about, need to really look inside yourself and say ‘can I buy and just sit there and leave that thing alone and not even think about fiddling with it for 20 years?’

And then I suggest you do this deal, find somebody that you trust completely, spouse, sibling, best friend, I don’t care who it is. And tell them about all this. And then make yourself a solemn vow that somehow you associate with that passive investment that you’ve invested in. And before you allow yourself to sell it, you have to go to them and say ‘remember, I promised to you that I would not sell this for 20 years? Well now I think things are different and I wanna sell it, and what do you say to me’, and you’ve already trained them to say you’re not gonna sell it for 20 years. But you what, most people would go ahead and sell it anyway.

Today, we’ll look at some stocks with solid revenue and cheap valuations, out of which the top ones are Nisun International Enterprise Development Group Co., Ltd (NASDAQ:NISN), Chimerix, Inc. (NASDAQ:CMRX), and United Maritime Corporation (NASDAQ:USEA).

Best Stocks to Buy for the Next 10 Years

Best Stocks to Buy for the Next 10 Years

Photo by Ruben Sukatendel on Unsplash

Our Methodology

We picked stocks that have a revenue growth higher than 25{1668a97e7bfe6d80c144078b89af180f360665b4ea188e6054b2f93f7302966b} annually, and then further filtered them with a positive price to earnings ratio (to ensure there is profitability). We preferred companies with the lowest PE ratios. They were then ranked in descending order of P/E ratios and the top ten are listed here.

Best Stocks to Buy for the Next 10 Years

10. Corebridge Financial, Inc. (NYSE:CRBG)

Trailing Twelve Month P/E: 1.59

Corebridge Financial, Inc. (NYSE:CRBG) is a financial services company headquartered in Houston, Texas. The firm provides retirement products such as annuities and mutual funds.

Corebridge Financial, Inc. (NYSE:CRBG)’s share price target was reduced to $23 from $26 by Credit Suisse in January 2023 as the bank shared that the firm’s shares might have a liquidity problem. 29 of the 943 hedge funds part of Insider Monkey’s Q4 2022 survey had bought the firm’s shares.

Chimerix, Inc. (NASDAQ:CMRX), Nisun International Enterprise Development Group Co., Ltd (NASDAQ:NISN), and United Maritime Corporation (NASDAQ:USEA) are met by Corebridge Financial, Inc. (NYSE:CRBG) in our list of great long term stocks.

9. Navios Maritime Partners L.P. (NYSE:NMM)

Trailing Twelve Month P/E: 1.51

Navios Maritime Partners L.P. (NYSE:NMM) is a marine shipping company that is headquartered in Monaco, Monaco. It operates dry bulk cargo vessels all over the world including in regions such as North America, Europe, and Australia. The firm has more than a hundred ships in its fleet.

Navios Maritime Partners L.P. (NYSE:NMM)’s fourth quarter results saw the firm’s revenue grow by more than $100 million annually to sit at $370 million. Six of the 943 hedge funds had held the firm’s shares during last year’s fourth quarter.

Navios Maritime Partners L.P. (NYSE:NMM)’s largest investor is Vadim Rubinchik’s Brightlight Capital which owns 373,800 shares that are worth $9.7 million.

8. Netcapital Inc. (NASDAQ:NCPL)

Trailing Twelve Month P/E: 1.43

Netcapital Inc. (NASDAQ:NCPL) is a financial services company that is headquartered in Boston, Massachusetts. The firm operates a funding portal that allows private companies to access a global base of investors to raise capital. It also provides valuation services, economic damage assessments, and more.

Netcapital Inc. (NASDAQ:NCPL) shook up its management team in January 2023 when it announced a new chief executive officer, as its former CEO became the top executive of its subsidiary. Two of the 943 hedge funds part of our database had invested in the company in last year’s fourth quarter.

7. Jiayin Group Inc. (NASDAQ:JFIN)

Trailing Twelve Month P/E: 1.41

Jiayin Group Inc. (NASDAQ:JFIN) is a Chinese financial services company that is headquartered in Shanghai, the People’s Republic of China. The firm allows borrowers and financial institutions to connect with each other and secure and provide products and services.

Jiayin Group Inc. (NASDAQ:JFIN)’s third quarter results saw the firm report $2.1 billion in loan origination, which marked for a strong 123{1668a97e7bfe6d80c144078b89af180f360665b4ea188e6054b2f93f7302966b} annual growth. Its target was small sized borrowers, with the average loan amount standing at roughly $1,200. This allowed the firm’s net revenue to grow by 55{1668a97e7bfe6d80c144078b89af180f360665b4ea188e6054b2f93f7302966b} annually as it posted $125.7 million in revenue. At the same time, its net income grew by 98.8{1668a97e7bfe6d80c144078b89af180f360665b4ea188e6054b2f93f7302966b} annually to sit at $34.9 million. Two of the 943 hedge funds polled by Insider Monkey had bought the firm’s shares in Q4 2022.

Jiayin Group Inc. (NASDAQ:JFIN)’s largest investor in our database is Jim Simons’ Renaissance Technologies which owns 21,896 shares that are worth $50,000.

6. Obsidian Energy Ltd. (NYSE:OBE)

Trailing Twelve Month P/E: 1.07

Obsidian Energy Ltd. (NYSE:OBE) is a Canadian oil and gas company headquartered in Calgary, Canada. The firm develops oil and gas exploration properties in Western Canada’s Sedimentary Basin.

Obsidian Energy Ltd. (NYSE:OBE)’s share price target was raised to CAD13 from CAD12.75 by Stifel in February 2023. The firm also kept a Buy rating on the stock.

The firm’s analyst explained that the company’s exploration properties in Alberta have strong returns and recycle ratios compared to other properties in North America. He added that the firm’s recent downsizing efforts were fueled by it assessing market conditions to decide how to respond to them in the wake of underlying commodity volatility. Insider Monkey dug through 943 hedge funds for last year’s fourth quarter and found out that 11 had held a stake in the company.

Peter Rathjens, Bruce Clarke, and John Campbell’s Arrowstreet Capital is Obsidian Energy Ltd. (NYSE:OBE)’s largest investor. It owns 1.2 million shares that are worth $8.1 million.

Nisun International Enterprise Development Group Co., Ltd (NASDAQ:NISN), Obsidian Energy Ltd. (NYSE:OBE), Chimerix, Inc. (NASDAQ:CMRX), and United Maritime Corporation (NASDAQ:USEA) are some high growth and cheap stocks.

 

Click to continue reading and see 5 Best Stocks to Buy for the Next 10 Years.

 

Suggested Articles:

Disclosure: None. 10 Best Stocks to Buy for the Next 10 Years is originally published on Insider Monkey.

Drug Formulation Market to Surpass US$ 1.58 Tn Amid Increasing Demand for Oral Formulation Booming the Pharmaceutical Industry Growth in Coming Years

Drug Formulation Market to Surpass US$ 1.58 Tn Amid Increasing Demand for Oral Formulation Booming the Pharmaceutical Industry Growth in Coming Years

East Asia drug formulation marker revenue valued to reach around US$ 320.7 Bn in 2032. Key Companies Profiled are- AstraZeneca plc., Bristol-Myers Squibb, Eli Lilly and Company, Gilead Sciences, Inc., Merck & Co., Inc., Novartis AG, Pfizer Inc., AbbVie Inc.

NEWARK, Del., Nov. 10, 2022 /PRNewswire/ — As per Future Market Insights, the global drug formulation market was valued at over US$ 1.50 Tn in 2021 and is expected to exhibit growth at a CAGR of 5.6{1668a97e7bfe6d80c144078b89af180f360665b4ea188e6054b2f93f7302966b} over the forecast period (2022-2032).

Future Market Insights Logo

Future Market Insights Logo

As pharmaceuticals enhance our quality of life, there is an increased demand for novel drugs formulation that would offer effective clinical care with a cost-effective manufacturing process. Biologics have proven to be an effective treatment option for chronic disease treatment. Pharmaceutical companies are being compelled by the rise of biosimilars to either innovate or lower prices to compete. This has been stimulating innovation in the field of biologics. As there are currently 37 approved biosimilars by the Food and Drug Administration (FDA). A significant portion of this expansion occurred in 2019 when the number of biosimilars that were approved increased by 65{1668a97e7bfe6d80c144078b89af180f360665b4ea188e6054b2f93f7302966b} and the number of such medicines that were made available in the United States increased by 157{1668a97e7bfe6d80c144078b89af180f360665b4ea188e6054b2f93f7302966b}.

Request Sample Report @ https://www.futuremarketinsights.com/reports/sample/rep-gb-15755

However, manufacturers, payers, and providers anticipate that biosimilar competition will result in persistent price reductions, as demonstrated by the adoption of biosimilars in Europe over the past 13 years.

Manufacturers will be encouraged to cut the prices of their products as the number of treatment options for a particular sickness or condition increases that expects to drive the drug formulation market growth in coming years.

Key Takeaways from Market Study

  • The oral formulation is expected to hold a 44.6{1668a97e7bfe6d80c144078b89af180f360665b4ea188e6054b2f93f7302966b} market value share by the end of 2032 and is expected to showcase growth at a CAGR growth of 6.0{1668a97e7bfe6d80c144078b89af180f360665b4ea188e6054b2f93f7302966b} over the forecast period.

  • Based on various indications, central nervous systems disorders hold the highest market share of 14.1{1668a97e7bfe6d80c144078b89af180f360665b4ea188e6054b2f93f7302966b} of the market share in 2021 and are projected to dominate throughout the forecast period.

  • In terms of end-user, the big pharma companies are expected to register a CAGR of 5.1{1668a97e7bfe6d80c144078b89af180f360665b4ea188e6054b2f93f7302966b} in upcoming years.

  • North America is slated to be the leading region with a value share of 48.1{1668a97e7bfe6d80c144078b89af180f360665b4ea188e6054b2f93f7302966b} at the end of the forecast period.

“Growing prevalence of chronic disorders and Rising needs for novel drug formulation in the pharmaceutical sectors is expected to witness the growth of Drug Formulation Market over the forecast period,” says an analyst of Future Market Insights.

Ask an Analyst @ https://www.futuremarketinsights.com/askus/rep-gb-15755

Market Competition

The drug formulation industry’s pharmaceutical and biotech businesses are concentrating on leveraging market potential by implementing mergers and acquisitions strategies. The trend continues as a result of the effective marketing campaign of novel and innovative drug formulation portfolios following strategic partnerships, acquiring their place in the market. The key techniques employed by the manufacturers to extend their business units and customer bases in both developed and emerging economies include strategic collaborations, mergers and acquisitions, production capacity expansions, and expanding product sales.

For instance,

  • The COVID-19 vaccine was developed by Pfizer with the assistance of Sanofi in 2021, and Bayer and CureVac formed a complex cooperation to distribute 160M doses of the vaccine by 2022.

  • The German mRNA CDMO AmpTec was acquired by Millipore Sigma, the life science division of Merck KGaA. This strengthened offerings across the mRNA value chain, especially for MilliporeSigma, which already supplies lipids to Pfizer-BioNTech for their COVID-19 vaccines. Lipids are the main mode of delivery for mRNA therapeutics.

Key Market Segments Covered in Drug Formulation Industry Research

By Dosage Form:

  • Oral formulations

  • Parenteral formulations

  • Topical formulations

  • Inhalation formulations

By Indication:

  • Infectious Diseases

  • Cancer

  • Cardiovascular Diseases

  • Diabetes

  • Respiratory Diseases

  • Central Nervous System Disorders

  • Autoimmune Diseases

  • Gastrointestinal Diseases

  • Musculoskeletal Disorders

  • Dermatological Disorders

  • Other

By End User:

By Region:

Report Customization available @ https://www.futuremarketinsights.com/customization-available/rep-gb-15755

Table of Content

1. Executive Summary

  1.1. Global Market Outlook

  1.2. Demand Side Trends

  1.3. Supply-Side Trends

  1.4. Analysis and Recommendations

2. Market Overview

  2.1. Market Coverage / Taxonomy

  2.2. Market Definition / Scope / Limitations

  2.3. Inclusion and Exclusion

3. Key Market Trends

  3.1. Key Trends Impacting the Market

  3.2. Product Innovation / Development Trends

Report Preview@ https://www.futuremarketinsights.com/reports/drug-formulation-market

Have a Look at Related Research Reports of Healthcare

Injectable Drug Delivery Market Size: Sales in the global Injectable Drug Delivery Market are slated to top US$ 41.5 Bn in 2022, projects Future Market Insights (FMI). Expanding at a healthy 8.9{1668a97e7bfe6d80c144078b89af180f360665b4ea188e6054b2f93f7302966b} CAGR, the market size is projected to total US$ 69.13 Bn by 2028

Therapeutic Drug Monitoring Market Share: The therapeutic drug monitoring market is projected to record a CAGR of 9.7{1668a97e7bfe6d80c144078b89af180f360665b4ea188e6054b2f93f7302966b} during the forecast period, up from US$ 1.5 Bn in 2020 to reach a valuation of US$ 2.9 Bn by 2026

Pharmaceutical Drug Delivery Market Trends: During the assessment period, the global Pharmaceutical Drug Delivery Market is expected to increase at a robust CAGR of 6{1668a97e7bfe6d80c144078b89af180f360665b4ea188e6054b2f93f7302966b}, from US$ 1600 Bn in 2021 to US$ 3000 Bn by 2032

Aseptic Formulation Processing Market Analysis: Aseptic formulation processing is the manipulation of sterile active pharmaceutical ingredient (APIs) or pharmaceutical product in a carefully controlled environment using aseptic technique in order to produce a sterile end product

Paediatric Wheelchairs Market Share: While there are a variety of products serving the needs of adult disability patients who need mobility support, there is also a niche market for paediatric wheelchairs that serve all the needs of the children who need assistance in mobility.

Healthcare IT Outsourcing Market Trends: The global healthcare IT outsourcing market is expected to reach a valuation of US$ 50,025.3 Million in 2022

Animal Healthcare Market Analysis: The animal healthcare market is valued at US$ 42.3 Billion in 2021. The market is likely to grow at a CAGR of 4.3{1668a97e7bfe6d80c144078b89af180f360665b4ea188e6054b2f93f7302966b} through 2027

Healthcare Interoperability Solutions Market Outlook: During the forecast period, the healthcare interoperability solutions market holds an average growth prospect with an anticipated CAGR of 14{1668a97e7bfe6d80c144078b89af180f360665b4ea188e6054b2f93f7302966b} to reach a valuation of US$ 5.5 Bn by 2026, from US$ 3.3 Bn in 2021

Pharmacy Refrigerators Market Analysis: The global pharmacy refrigerators market is estimated to be valued US$ 552.3 million in 2022, rising to US$ 1,027 million by 2032

Removable Partial Dentures Market Size: The global pharmacy refrigerators market is estimated to be valued US$ 552.3 million in 2022, rising to US$ 1,027 million by 2032

About Future Market Insights, Inc.

Future Market Insights, Inc. is an ESOMAR-certified business consulting & market research firm, a member of the Greater New York Chamber of Commerce and is headquartered in Delaware, USA. A recipient of Clutch Leaders Award 2022 on account of high client score (4.9/5), we have been collaborating with global enterprises in their business transformation journey and helping them deliver on their business ambitions. 80{1668a97e7bfe6d80c144078b89af180f360665b4ea188e6054b2f93f7302966b} of the largest Forbes 1000 enterprises are our clients. We serve global clients across all leading & niche market segments across all major industries.

Contact Us:

Future Market Insights Inc.  
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA  
T: +1-845-579-5705  
For Sales Enquiries: sales@futuremarketinsights.com   
Browse Latest Market reports: https://www.futuremarketinsights.com/reports

Logo: https://mma.prnewswire.com/media/1197648/FMI_Logo.jpg

Cision

Cision

View original content:https://www.prnewswire.com/news-releases/drug-formulation-market-to-surpass-us-1-58-tn-amid-increasing-demand-for-oral-formulation-booming-the-pharmaceutical-industry-growth-in-coming-years–future-market-insights-inc-301674518.html

SOURCE Future Market Insights